Society for Cardiovascular Angiography and Interventions (SCAI) 2021 Scientific Sessions

Virtual 28 April 2021 - 01 May 2021

Minority of SIHD patients undergoing PCI meet ISCHEMIA trial criteria

15 Jun 2021 by

Only a small fraction of patients with stable ischaemic heart disease (SIHD) who undergo percutaneous coronary intervention (PCI) in the US meet the inclusion criteria of the ISCHEMIA* trial, according to results of a study presented at SCAI 2021.

Minority of SIHD patients undergoing PCI meet ISCHEMIA trial criteria

15 Jun 2021

Robotic PCI shows high success rates in real-world setting

27 May 2021 by

A robotic-assisted percutaneous coronary intervention (PCI) approach showed high clinical and technical success rates across all degrees of lesion complexity among patients with coronary artery disease (CAD), according to the final results of the PRECISION GRX* study presented at SCAI 2021.

Robotic PCI shows high success rates in real-world setting

27 May 2021

One-month DAPT sufficient after PCI?

24 May 2021 by

Two separate analyses presented at SCAI 2021 demonstrated that a 1-month dual antiplatelet therapy (DAPT) following percutaneous coronary intervention (PCI) with a drug-eluting stent (DES) appears to be safe and effective for PCI patients at high risk of bleeding (ie, those with advanced age, chronic NSAID use, bleeding history, anaemia, thrombocytopenia, etc), compared with a DAPT regimen between 6 and 12 months.

One-month DAPT sufficient after PCI?

24 May 2021

Long-term DAPT should remain SoC post-PCI in high-risk ACS patients

20 May 2021 by

Dual antiplatelet therapy (DAPT) for >12 months should remain the standard of care (SoC) for high-risk patients with acute coronary syndrome (ACS) who have undergone percutaneous coronary intervention (PCI), suggested a study presented at SCAI 2021.

Long-term DAPT should remain SoC post-PCI in high-risk ACS patients

20 May 2021